Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Executive Summary

BEECHAM's NEW CHAIRMAN WILL BE ROBERT BAUMAN, 55, the current vice chairman of Textron, the Providence, R.I.-based aerospace, financial services and consumer products conglomerate announced August 4. Bauman, the first American appointed to head Beecham, will succeed acting chairman Sir Keith of Castleacre at the top management spot for the British pharmaceutical and consumer products business. The appointment becomes effective September 15. Bauman joined Textron in 1985 after that company acquired Avco Corporation, where Bauman was chairman and chief exec. Prior to joining Avco in 1981, Bauman was with General Foods for 23 years -- the last seven years as president of the company's international operations. Bauman graduated from Ohio Wesleyan and holds an MBA from Harvard. Although he brings to Beecham hands-on experience managing a large multi-national conglomerate, Bauman has no experience with pharmaceuticals. As the company puts greater emphasis on its drug business, responsibility for the growth of that business segment will fall to Pharmaceutical Group President James Pollard, head of Beecham's worldwide pharmaceutical business. Beecham acquired the Norcliff Thayer OTC business from Revlon in December and recently announced that its Germaine Monteil cosmetics business is for sale. In its just-released annual report for fiscal 1986 ended March 31, Beecham said it paid $368.7 mil. for Norcliff Thayer, whose annual sales under Revlon were roughly $150 mil. In fiscal 1986, Beecham's worldwide pharmaceutical sales increased approximately 30% (in dollars) to $1.27 bil. with Rx sales accounting for approximately $1.04 bil. and OTC product sales approximately $230 mil. Measured in pounds sterling, Beecham pharmaceutical sales were up 8.3% to (BRITISH POUND)862.

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts